Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Cesare Casadei"'
Autor:
Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induce
Externí odkaz:
https://doaj.org/article/e1df2d0bb34a4efe88e26cf19e6d58b1
Autor:
Margherita Trebbi, Cesare Casadei, Silvia Dari, Andrea Buzzi, Mario Luciano Brancaccio, Valentina Feletti, Alessandro Mussetto
Publikováno v:
Diagnostics, Vol 13, Iss 6, p 1112 (2023)
Background and Aim: Double-balloon enteroscopy (DBE) is a well-established procedure for direct visualisation of the entire small bowel mucosa, and, in contrast with other imaging techniques, allows to perform biopsies and therapeutic interventions.
Externí odkaz:
https://doaj.org/article/e4f9195733ec4bd3bbbf21e67e13b0f8
Autor:
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical
Externí odkaz:
https://doaj.org/article/2597c903fe2c465ea68be45f74e33152
Autor:
Brigida Barberio, Sonia Facchin, Edoardo Mele, Renata D’Incà, Giacomo Carlo Sturniolo, Fabio Farinati, Fabiana Zingone, Andrea Quagliariello, Matteo Ghisa, Davide Massimi, Cesare Casadei, Edoardo Vincenzo Savarino
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background: Faecal microbiota transplantation (FMT) is a reasonable therapeutic option for the treatment of Clostridioides difficile infection (CDI) recurrent and refractory (RCDI) to therapy, but little evidence on the long-term impact of this thera
Externí odkaz:
https://doaj.org/article/9bf37f483c78411abce9daafe50a7303
Publikováno v:
Gastrointestinal Endoscopy.
Autor:
Lorenzo Bertani, Brigida Barberio, Marco Fornili, Luca Antonioli, Federico Zanzi, Cesare Casadei, Laura Benvenuti, Sonia Facchin, Vanessa D'Antongiovanni, Greta Lorenzon, Linda Ceccarelli, Laura Baglietto, Nicola de Bortoli, Massimo Bellini, Francesco Costa, Edoardo Vincenzo Savarino, Matteo Fornai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26a5f35c440ca4111bdb8374d9cea579
http://hdl.handle.net/11577/3457528
http://hdl.handle.net/11577/3457528
Publikováno v:
Gastroenterology. 160:e1-e3
Autor:
Nicola Ferri, Cesare Casadei, Davide Massimi, Carla Marinelli, A. Gubbiotti, Renata D'Incà, Edoardo Savarino, Fabiana Zingone, Brigida Barberio, Raffaella Marin, Maria Giovanna Lupo
Publikováno v:
Journal of clinical gastroenterology. 56(9)
Background/goal Ulcerative colitis (UC) is characterized by chronic inflammation and progressive course, with potential extraintestinal complications including cardiovascular mortality. Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) leve
Autor:
Cesare Casadei, Antonio Ferronato, Fabiana Zingone, Brigida Barberio, Davide Massimi, Sonia Facchin, Linda Cingolani, Lorenzo Bertani, Renata D'Incà, Edoardo Savarino, Romilda Cardin, Francesco Costa
Publikováno v:
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb289286fa8687b77498cf580346cf4
http://hdl.handle.net/11577/3401603
http://hdl.handle.net/11577/3401603
Autor:
Maria Giulia Demarzo, Antonio Ferronato, Piera Melatti, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Edoardo Savarino, A. Gubbiotti, Fabiana Zingone, Linda Cingolani, Renata D'Incà, Cesare Casadei, Davide Massimi, Giorgia Bodini
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports
Scientific Reports
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd1d480555950479581b5e09cd67ef8
http://hdl.handle.net/11577/3394280
http://hdl.handle.net/11577/3394280